Paul Tudor Jones Geron Corp Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $19,981 - $23,820	-9,843 Reduced 8.82%	101,782 $246,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $144,677 - $254,701	86,633 Added 346.64%	111,625 $261,000
Q1 2021 May 17, 2021	BUY	$1.52 - $2.1 $37,987 - $52,483	24,992 New	24,992 $39,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $25,504 - $48,146	-26,025 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $45,804 - $166,039	26,025 New	26,025 $46,000
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $74,322 - $245,550	-41,062 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$1.8 - $2.32 $12,654 - $16,309	7,030 Added 20.66%	41,062 $74,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $67,723 - $90,184	34,032	34,032 $74,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.1B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.